CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题：Updates on Therapeutic Strategies in the Treatment of Relapsed/Refractory Multiple Myeloma.
Updates on Therapeutic Strategies in the Treatment of Relapsed/Refractory Multiple Myeloma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
多发性骨髓瘤是一种以单克隆B细胞增殖为特征的异质性疾病，目前尚无治愈性治疗方法。不幸的是，一线治疗后复发很常见。虽然复发难治性多发性骨髓瘤的预后通常较差，但复发/难治性多发性骨髓瘤治疗的进展带来了希望。然而，靶向治疗中有效选择的扩展带来了新的乐观和希望，即对旧疗法失败的患者可能对更新的模式产生应答，这些模式通常联合使用。我们按作用机制、疗效、获批场景和不良事件对目前获批的和新型研究性药物进行分类综述。我们深入探讨复发/难治性多发性骨髓瘤治疗的未来方向，综述未来的新型药物和治疗靶点。
Multiple myeloma is a heterogeneous condition characterized by the proliferation of monoclonal B-cells, for which there is currently no curative treatment available. Relapses are, unfortunately, common after first-line treatment. While the prognosis for relapsed refractory multiple myeloma is generally poor, advances in the treatment of relapsed or refractory multiple myeloma offer hope.
However, the expansion of effective options in targeted treatment offers renewed optimism and hope that patients who fail on older therapies may respond to newer modalities, which are often used in combination.
We review currently approved and novel investigational agents classified by mechanisms of action, efficacy, approved setting, and adverse events.
We delve into future directions of treatment for relapsed/refractory multiple myeloma, reviewing novel agents and therapeutic targets for the future.
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。
